The role of montelukast in the prevention and treatment of bronchopulmonary dysplasia in premature infants
10.3760/cma.j.issn.1673-4408.2021.09.009
- VernacularTitle:孟鲁司特防治早产儿支气管肺发育不良的研究进展
- Author:
Xia CHEN
;
Fei BEI
- Keywords:
Premature infant;
Bronchopulmonary dysplasia;
Montelukast;
Leukotriene receptor antagonist
- From:
International Journal of Pediatrics
2021;48(9):619-622
- CountryChina
- Language:Chinese
-
Abstract:
Bronchopulmonary dysplasia is one of the most common chronic respiratory diseases in premature infants, especially in very low birth weight infants.Lung immaturity, inflammatory injury, oxidative stress and abnormal repair after injury are the important factors.Leukotriene is an inflammatory mediator of 5-lipoxygenase pathway and participates in the occurrence of bronchopulmonary dysplasia.Montelukast, as a leukotriene receptor antagonist, may play a role in the treatment of bronchopulmonary dysplasia through anti-inflammation, anti-oxidation and anti-fibrosis.This article will review the potential mechanism and related clinical researches of montelukast which is used in treating bronchopulmonary dysplasia.
